Results 1 to 10 of about 159,255 (312)
Identifying potential biomarkers of idiopathic pulmonary fibrosis through machine learning analysis
Scientific Reports, 2023 Idiopathic pulmonary fibrosis (IPF) is the most common and serious type of idiopathic interstitial pneumonia, characterized by chronic, progressive, and low survival rates, while unknown disease etiology.
Zenan Wu +7 more
doaj +2 more sources
Regulatory Immune Cells in Idiopathic Pulmonary Fibrosis: Friends or Foes?
Frontiers in Immunology, 2021 The immune system is receiving increasing attention for interstitial lung diseases, as knowledge on its role in fibrosis development and response to therapies is expanding. Uncontrolled immune responses and unbalanced injury-inflammation-repair processes
Chiel van Geffen +10 more
doaj +2 more sources
Idiopathic pulmonary fibrosis: current diagnosis and treatment [PDF]
Jornal Brasileiro de Pneumologia, 2023 Idiopathic pulmonary fibrosis (IPF) is a devastating chronic lung disease without a clear recognizable cause. IPF has been at the forefront of new diagnostic algorithms and treatment developments that led to a shift in patients’ care in the past decade ...
Alexandre Franco Amaral +2 more
doaj +1 more source
American Journal of Respiratory and Critical Care Medicine, 2022 Background This American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior idiopathic pulmonary fibrosis (IPF) guidelines and addresses the progression of ...
G. Raghu +40 more
semanticscholar +1 more source
Global incidence and prevalence of idiopathic pulmonary fibrosis
Respiratory Research, 2021 Background Idiopathic pulmonary fibrosis (IPF) is a progressive debilitating lung disease with considerable morbidity. Heterogeneity in epidemiologic studies means the full impact of the disease is unclear.
T. Maher +7 more
semanticscholar +1 more source
Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis
Drugs, 2023 Idiopathic pulmonary fibrosis (IPF) remains a disease with poor survival. The pathogenesis is complex and encompasses multiple molecular pathways. The first-generation antifibrotics pirfenidone and nintedanib, approved more than 10 years ago, have been ...
F. Bonella +2 more
semanticscholar +1 more source
IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis.
PLoS ONE, 2021 Idiopathic pulmonary fibrosis is a chronic, fibrosing interstitial pneumonia that presents with various clinical courses and progression ranging from rapid to slow.
Yu Nakanishi +11 more
doaj +1 more source
International Journal of Molecular Sciences, 2023 Pirfenidone and nintedanib are antifibrotic medications approved for idiopathic pulmonary fibrosis treatment by regulatory agencies and available for clinical use worldwide.
F. Amati +6 more
semanticscholar +1 more source
Pulmonary Circulation, 2021 The implications of the recent change in the definition of pulmonary hypertension on epidemiology and outcomes are not known. We sought to determine the percentage of patients with the two most common lung diseases that would be reclassified regarding ...
Steven D. Nathan +7 more
doaj +1 more source
Frontiers in Medicine, 2022 Patients with idiopathic pulmonary fibrosis are screened for circulating autoantibodies as part of the initial interstitial lung disease workup. Management of seropositive idiopathic pulmonary fibrosis is currently considered no different than that of ...
Paraskevi Kirgou +8 more
doaj +1 more source